ЛИТЕРАТУРА

1. Гориловскип Л.М., Велигура В.И., Вязенкин С. М. и др. Морфологическая характеристика рака предстательной железы по результатам биопсии. — Материалы Пленума правления Российского общества урологов. — Омск, 1999. — С. 54.

2. Грачева Л.С. Выявление и предоперационный прогноз клинически незначимого рака предстательной железы // РМЖ. — Т. 5. —№4- 1997.

3. Лоран О.Б., Пушкарь Д.Ю., Франк Г.А. Простат-специфический антиген и морфологическая характеристика рака предстательной железы: Руководство для врачей. — М.: МЕДпресс, 1999.

4. Лоран О.Б., Пушкарь Д.Ю., Степанов В.П., Крохотина Л.В. Дифференциальная диагностика опухолей предстательной железы с помощью определения уровня простат-специфического антигена сыворотки крови. — М., 2000.

5. Мазо Е.Б., Мешков В.В. Клинические, лабораторные и морфологические особенности предрака предстательной железы//Урол. и нефрол. - 1999. - №4. - С. 49.

6. Мазо Е.Б., Мешков В.В. Простатическая интраэпителиальная неоплазия: Пособие для врачей. — М.: Гэотар-Мед, 2001.

7. Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. -М., 1999.

8. Мешков В.В. Клинические, лабораторные и морфологические особенности простатической интраэпителиальной неоплазии: Автореф. дис. канд. мед. наук. — М., 2001.

9. Петров С. В., Велиев Е.И., Харитонов П.Н. Сопоставление эффективности различных методик трансректальной мультифокальной пункционной биопсии предстательной железы под ультразвуковым контролем. — Современные возможности и новые направления в диагностике и лечении рака почки, мочевого пузыря, предстательной железы: Материалы Всероссийской научно-практической конференции. — Уфа: Здравоохранение Башкортостана, 2001. — С. 88-89.

10. Пушкарь Д.Ю. Радикальная простатэктомия. — М.: МЕДпресс-информ, 2002.

11. Степанов В.Н., Франк Г.А., Джиоев P.P. Интраэпителиальная неоплазия простаты // Урол. и нефрол. - 1999. - №1. - С. 16-19.

12. Федосенко К.В., Прочуханова А.Р., Прочуханов Р.А. Экспертная автоматизированная система диагностики доброкачественных и злокачественных новообразований эндометрия и предстательной железы: Пособие для врачей / Под ред. Г.Б.Ковальского. - СПб, 2000. - С. 16-22.

13. Шульпекова Ю. Рак предстательной железы // РМЖ. —1999.-Т. 7-№10.

14. Aamink R.G., Detarosette J.J., Huynen A.L. et al. Standardized assessment to enhance the diagnostic value of prostate volume: Correlation with prostate-specific antigen levels // Prostate. - 1996. - Vol. 29. - P. 327-333.

15. Alavi A.S., Solov/ay M.S., Vaidya A. et al. Local anesthesia for ultrasound guided prostate biopsy: a prospective randomized trial comparing 2 methods//J. Urol. - 2001.-Vol. 166.-P. 1343-1345.

16. Allen E.A., Kahane H, Epstein J.I. Repeat biopsy strategies formen with atypical diagnoses on initial prostate needle biopsy // Urology. -1998.-Vol. 52.-P. 803-807.

17. Agha A.H., Schechter E., RoyJ.B. et al. Prostate specific antigen is metabolized in the liver // J. Urol. (Baltimore). - 1996. - Vol. 155. -P. 1332-1335.

18. AkdasA., Tarean Т., Turkeri L. et al. The impact of prostate-specific antigen density in predicting prostate cancer when serum prostatespecific antigen levels are less than 10 ng/ml // Eur. Urol. — 1996. — Vol. 29.-P. 189-192.

19. Alexander E.E., Qian J.Q., Wollan P.C. et al. Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration // Urology. - 1996. - Vol. 47. - P. 693-698.

20. Alivizatos G., Deliveliotis C, Mitropoulos D. et al. Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy? // Urology. - 1996. - Vol. 48 (Suppl.). - P. 71-75.

21. ArcangeliC.G., Humphrey P.A., Smith D.S. et al. Percentage of free serum PSA as a predictor of the pathological features of prostate cancer in a screening population // Urology. - 1998. - Vol. 51. - P. 558.

22. Aron M., Rajeev T.P., Gupta N.P. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study // BJU Int. - 2000. - Vol. 85 (Suppl. 6). - P. 682-685.

23. Aubert J. Complications des biopsies prostatiques. Analyse d'uneserie de 4764 biopsies // Prog. Urol. - 1992. - Vol. 2. - P. 484-487.

24. Aus G., Ahlgren G., BergdahlS. et al. Infection after transrectal core biopsies of the prostate - risk factors and antibiotic prophylaxis // BJU. -1996 — Vbl. 77. - P. 851—855.

25. Aus G., BergdahlS., Prosing R. et al. Reference range of prostatespecific antigen after transurethral resection of the prostate // Urology. —1996.-Vol. 47.-P. 529-531.

26. AusG., BergdahlS., Hugosson S. et al. Outcome of laterally directed sextant biopsies of the prostate in screened males aged 5 0—66 years //Eur. Urol. - 2001. - Vol. 39. - P. 655-661.

27. Auvinen A., Tammela Т., Stenman U.H. et al. Screening for prostate cancer using serum prostate-specific antigen: A randomised, population-based pilot study in Finland // Brit. J. Cancer. — 1996. — Vol. 74. —P. 568-572.

28. Babaian R.J., Mettlin C, Kane R. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography: findings of the American Cancer Society National Prostate Cancer Detection Project // Cancer. - 1992. - Vol. 69. - P. 1195-1200.

29. Babajan R.J. Detection of prostate specific antigen in pancreas and salivary glands: A potential impact on prostate cancer overestimation//J. Urol. (Baltimore). - 1996. - Vol. 156. - P. 468.

30. Babaian R. Extended field prostate biopsy enhances cancer detection // Urology. - 2000. - Vol. 55. - P. 453-456.

31. Babaian R.J., Kojima M., Ramirez E.L. et al. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer//J. Urol. (Baltimore). - 1996. -Vol. 156. - P. 432-437.

32. Babaian R.J., Toi A., Kamoi K. et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy // J.Urol. - 2000. - Vol. 163 (Suppl. 1). - P. 152-157.

33. Badalament R.A., Miller M.C., Peller P. A. et al. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level // J. Urol. —1996. -Vol. 156. - P. 1375-1380.

34. Baffa R., Moreno J.G., Monne M. et al. A comparative analysis of prostate-specific antigen gene sequence in benign and malignant prostatetissue // Urology. - 1996. - Vol. 47. - P. 795-800.

35. Ban Y, Wang M.C., Watt K.W. et al. The proteolytic activity of human prostate-specific antigen // Biochem. Biophys. Res. Commun -1984. - Vol. 123. - P. 482-488.

36. Bangma C.N., Kranse R., Blijenberg B.G. et al. The value of screening test in the detection of prostate cancer: part I - results of a retrospective evaluation of 1726 men // Urology. - 1995. - Vol 46 (Supnl 6) -P. 773-778.

37. Bangma C.H., Kranse R., Schroder F.H. Free serum prostate-specific antigen and screening for prostate cancer // JAMA - 1996 -Vol. 275. - P. 837-838.

38. Bangma C.N., Kranse R., Blijenberg B.G., Schroder F.H. The free-to-total serum prostate specific antigen ratio for staging prostatic carcinoma /JJ-. Urol. - 1997. - Vol. 157 (Suppl. 2). - P. 544-547.

39. Barthelemy Y, Gasman D., Bellot J. et al. Valeur prognostique d'une biopsie prostatique echoguidee positive sur Ie volume tumoral et Ie caractere intracapsulaire de l'adenocarcinome prostatique // Prog Urol — 1996. - Vol. 6. - P. 920-925.

40. Bassily N.H., Manley S.C., Wojno K.J. et al. Perineural invasion on prostate needle biopsy independent predictor of stage T 3-4 disease // Mod. Pathol - 1999. - Vol. 12. - P. 89A.

41. Bastacky S.I., Walsh P.C, Epstein J.I. et al. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage В adenocarcinoma of the prostate // Am J. Surg Pathol. - 1993. - Vol. 17. - P. 336-341.

42. Bauer J.J., Zeng J., Weir J. et al. Three-dimensional computersimulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer // Urology. - 1999. - Vol. 53 (Suppl 5) - P. 961-967.

43. Bazinet M., MeshrefA.W., JrudelC. et al. Prospective evaluation of prostate specific antigen density and systemic biopsies for detection of prostatic carcinoma // Urology. - 1994. - Vol. 43. - P. 44-52.

44. Bazinet M., Karakiewicz P. I., Aprikan A.G. etal. Value of system atic transition zone biopsies in the early detection of prostate cancer// J Urol. - 1996. - Vol. 155. - P. 605-606.

45. Becker C, Piironen T. et al. Clinical value of human glandular kallikrein 2 and free and total prostate specific antigen in serum form a population of men with prostate specific antigen levels 3,0 ng/ml orgrater// Urology. - 2000 - Vol. 55 (Suppl. 5). - P. 694-699.

46. Beerlage H.P., De Reijke T.M., De la Rosette J.J. Conciderations regarding prostate biopsies // Eur. Urol. - 1998. - Vol. 34. - P. 303-312.

47. Benson N.C., Wang I.S., Ponluck K.A. et al. Prostate specific antigen density: a means of distinguishing benign prostatic hyperplasia and prostate cancer//J. Urol.- 1992. -Vol. 147. - P. 815-819.

48. Benson M.C., Whang I.S., Olsson C.A. et al. The use of prostatespecific antigen density (PSAD) to enhance the predictive value of intermediate levels of serum PSA//J. Urol. - 1992.-Vol. 147-P. 817-821.

49. Benson M.C., Olsson M.D. Prostate specific antigen and prostate specific antigen density: roles in patient evaluation and management // Cancer. - 1994. - Vol. 74 - P. 1667-1673.

50. Berner A., Skjorten F.G., Fossa S.D. Follow-up of prostatic intraepithelial neoplasia // Eur. Urol. - 1996. - Vol. 30. - P. 256-260.

51. Beurton D., Barthelemy Y., Fontaine E. Twelve systematic prostate biopsies are superior to sextant biopsies for diagnosing carcinoma: a prospective randomized study // Br. J. Urol. - 1997. - Vol. 80. - P. 239.

52. Bjork Т., Bjanell A., Abrahamsson P. A. et al. Alpha 1-antichymotrypsin production in PSA producing cells is common in prostate cancer but rare in benign prostatic hyperplasia//Urology. — 1994. — Vol.43. —P. 427-434.

53. Bjork Т., Piironen Т., Peltersson K. et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer // Urology. — 1996. — Vol. 48. —P. 882-888.

54. BluteM.E, Bergsrtalh E.J., Partin A.W. et al. Validation of Partin tables for predict pathological stage of clinically localized prostate cancer//J. Urol. - 2000-Vol. 165.-P. 1591-1595.

55. Blute M.L., Bergstralh EJ. el al. Use of Gleason score, prostatespecific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy // J. Urol. - 2001. - Vol. 165. -P. 119-125.

56. Borboroglu P. G., Comer S.W., Rifenburgh R.H. et al. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies // J. Urol. - 2000. - Vol. 163. - P. 158-162.

57. Borboroglu P. G., Amling C.L. Correlation of positive prostate sextant biopsy locations to sites of positive surgical margins in radical prostatectomy specimens // Eur. Urol. - 2001. - Vol. 39. - P. 648-654.

58. Bostwick D.G., Brawer M.K. Prostatic intraepithelial neoplasia and early invasion in prostate cancer // Cancer. — 1987. — Vol. 59. — P. 788-794.

59. Bostwick D.G. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies // Am. J. Surg. Pathol. - 1994. - Vol. 18. - P. 796-803.

60. Bostwick D.G., Qian J., Bergstralh E. et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer // J. Urol. —1996. -Vol. 155 (Suppl. 4). - P. 1361-1367.

61. Bostwick D.G., Wheeler T.M., Blute M. et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies // Urology. - 1996. - Vol. 48. - P. 47-57.

62. Bostwick D.G. Evaluating prostate needle biopsy: Therapeutic and prognostic importance // CA Cancer. J. Clin. — 1997. — Vol. 47. —P. 297-319.

63. Brawer M.K., Beatie J., Wener M.H. et al. Screening for prostatic carcinoma with prostate specific antigen: results of the second year // J. Urol. - 1993. - Vol. 150. - P. 106-109.

64. Brawer M.K. Prostate specific antigen: current status // Cancer. J. Clin. - 1999. - Vol. 49. - P. 264.

65. Breu J., Pick! U., SchaffJ. Extraprostatic production of prostate specific antigen is under hormonal control // J. Urol. (Baltimore). —1997.-Vol. 157.-P. 212-213.

66. BrinkerD.A., RossJ.S., Tran Т.Н. et al. Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade? //J. Urol. - 1999. - Vol. 162. - P. 2036-2039.

67. Brossner C, Bayer G., Madersbacher S. et al. Twelve prostate biopsies detect significant cancer volumes // BJU Int. - 2000. - Vol. 85 (Suppl. 6). - P. 705-707.

68. Brossner C, Madersbacher S., Bayer G. et al. Comparative study of two different TRUS-guided sextant biopsy techniques in detecting prostate cancer in one biopsy session // Eur. Urol. — 2000. — Vol. 37 (Suppl. 1). —P. 65-71.

69. Carter H.B., Pearson J.D., Metier E.J. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease // JAMA. - 1992. - Vol. 267. - P. 2215-2220.

70. Carter H.B., Pearson J.D., Waclawiw Z. et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity // Urology. — 1995. — Vol. 45. —P. 591-596.

71. CarvalhalG.F, Smith D.S., Mager D.E. et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less // J. Urol. - 1999. - Vol. 161. - P. 835.

72. Catalona W., Smith D., RatliffT. et al. Measurement of prostatespecific antigen in serum a screening test for prostate cancer // New Engl. J. Med. - 1991. -Vol. 324. - P. 1156-1161.

73. Catalona W., Smith D., RatliffT. et al. Detection of organcon fined prostate cancer is increased through prostate-specific antigen-based screening//JAMA. - 1993. -Vol. 270. - P. 948-954.

74. Catalona W.J., Richie J.P., Ahmann F.R. et al. Comparison of digital rectal examination and serum PSA in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men // J. Urol. —1994. -Vol. 151. - P. 1283-1290.

75. Catalona W.J., Richie J.P., deKernion J.B. et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating charac teristic curves//J. Urol. - 1994.-Vol. 152.-P. 2031-2036.

76. Catalona W.J., Smith D.S., Wolfert R.L. et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity prostate cancer screening // JAMA. - 1995. - Vol. 274 (Suppl. 5). -P. 1214-1220.

77. Catalona W.J. Clinical utility of measurements of free and total prostate-specific antigen (PSA) // Prostate. - 1996. - Suppl. 7. -P. 64-69.

78. Catalona W.J., Smith D.S. Free serum prostate-specific antigen and screening for prostate cancer // JAMA. - 1996. - Vol. 275. - P. 838.

79. Catalona W.J., Hudson M.A., Scardino P. T. et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves // J. Urol. (Baltimore). - 1996. -Vol. 155. - P. 1396.

80. Catalona W.J., Partin A.W., Sllawin K.M. et al. Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial//JAMA.- 1998.-Vol. 279 (Suppl. 19). - P. 1542-1547.

81. Cevik L, Turkeri L.N., Ozveri H. et al. Short-term effect of digital rectal examination on serum prostate-specific antigen levels // Eur. Urol. - 1996. - Vol. 29. - P. 403-406.

82. Chan T.Y., Epstein J.I. Follow-up of atypical prostate needle biopsies suspicious for cancer // Urology. - 1999. - Vol. 53. - P. 351-355.

83. Chang JJ., Shinohara K., Bhargava V. et al. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection // J. Urol. - 1998. -Vol. 160 (Suppl. 6, Pt. 1). - P. 2111-2115.

84. ChangJ.J., Shinohara K., Hovey R.M. et al. Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection // Urology. - 1998. - Vol. 52. - P. 89-93.

85. Chang S.S., Alberts G., Wells N. el al. Intrarectal lidocaine during transrectal prostate biopsy: results of a prospective double-blind randomized trial // J. Urol. - 2001. - Vol. 166. - P. 2178-2180.

86. Chen Y.T., LudererA.A., Thiel R.P. et al. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer // Urology. — 1996. - Vol. 47. —P. 518-524.

87. Chen M.E., Troncoso P., Johnston D.A. et al. Optimization of prostate biopsy strategy using computer based analysis // J. Urol. —1997.-Vol. 158.-P. 1268.

88. Chen M.E., Troncoso P., Tang K. et al. Comparison of prostate biopsy schemes by computer simulation // Urology. — 1999. — Vol. 53 (Suppl. 5).-P. 951-960.

89. Chen M.E., Johnston D.A., Tang K. et al. Detailed mapping of prostate carcinoma foci: biopsy strategy implications // Cancer. — 2000. —Vol. 89 (Suppl. 8). - P. 1800-1809.

90. Christensson A., Laurell C.B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors // Europ. J. Biochem. - 1990. - Vol. 194. - P. 755-763.

91. Christensson A., Bjork Т., Nilsson O. et al. Serum prostate specific antigen complexed to alphal-antichymotrypsin as an indicator of prostale cancer//J. Urol. (Baltimore). - 1993. - Vol. 150. - P. 100-105.

92. Christensson A., Lilja H. Complex formation between protein С inhibitor and prostate-specific antigen in vitro and in human semen //Europ. J. Biochem. - 1994. -Vol. 220. - P. 45-53.

93. Chybowski F.U., Keller J.J.L., Bergstrahl E.J., Oesterling J.E. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters//J. Urol. - 1991. -Vol. 145. - P. 313-318.

94. Clements R., Aideyan O.U., Griffiths G.J. et al. Side effects and patient acceptability of transrectal biopsy of the prostate // Clin. Rad. —1993.-Vol. 47.-P. 125.

95. Cockett A.Т.К. Local recurrence after radical prostatectomy; Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins//Urology. - 1996. -Vol.47. - P. 231.

96. Coetzee L.J., Hars V., Paulson D.F. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy // Urology. - 1996. - Vol. 47. - P. 232-235.

97. Cohen R.J., Chan W.C., Edgar S.G. et al. Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma // BJU. - 1998. -Vol. 81. - P. 413-418.

98. CollinsG.N., LloydS.N., HehirM. et al. Multiple transrectalultra sound-guided prostatic biopsies — true morbidity and patient acceptance // Br. J. Urol. - 1993. - Vol. 71. - P. 460.

99. Collins G.N., Lee R.J., McKelvie G.B. et al. Relationship between prostate specific antigen, prostate volume and age in the benign prostate //Brit. J. Urol. - 1993. - Vol. 71. - P. 445.

100. Connolly J.A., Shinohara K., Presti J.C. et al. Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins // Urology. —1996.-Vol. 47.-P. 225-231.

101. Conrad S., Graefen M., Pichlmeier U. el al. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metatases in patients with clinically localized prostatic carcinoma // J. Urol. —1998.-Vol. 159.-P. 2023.

102. ConradS., Hautmann S.H., Henke R.P. et al. Detection and characterization of early prostate cancer by six systematic biopsies and fine needle aspiration cytology in prostates from bladder cancer patients // Eur. Urol. - 2001. - Vol. 39 (Suppl. 4). - P. 25-29.

103. Cookson M.S., Fleshner N.E., Soloway S.M. et al. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications // J. Urol. — 1997. — Vol. 157. —P. 559-562.

104. Cooner W.H., Mosley B.R., Rutherfoid C.L. et at. Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer // J. Urol. - 1988. - Vol. 139 (Suppl. 4). - P. 758-761.

105. Cooner W.H., Mosley B.R., Rutherford C.L. et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen // J. Urol. — 1990. — Vol. 143. —P. 1146-1154.

106. Cooner W.H. Early diagnosis of prostate cancer // Campbell's Urology- 1993.-P. 1.

107. Cooner W.H., Jacobsen S.J., Oesterling J.E. Age-specific PSA reference ranges compared with the 0,0—4,0 ng/ml reference range in men >60 years of age //J. Urol. (Baltimore). - 1994. - Vol. 151. - P. 449A.

108. Cooper C.S., Macindoe J.H., Perry P.J. et al. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men // J. Urol. (Baltimore). - 1996. - Vol. 156. - R 438-441.

109. Cormio L., Sblendorio D., Barberini M. et al. Antimicrobial prophylaxis for transrectal prostatic biopsy: a randomized prospective study comparing ciprofloxacin with piperacillin-tazobactam // Eur. Urol. —2000. - Vol. 37 (Suppl. 2). - P. 46.

110. CornudF., Belin X., Piron D. et al. Color Doppler-guided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for nonpalpable lesions // Urology. — 1997. — Vol. 49 (Suppl. 5).-P. 709-715.

111. Crawford E.D., Deantoni E.P., Etzioni R. et al. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program // Urology. —1996. - Vol. 47. - P. 863-869.

112. Crawford E.D., Hirano D., Werahera P. N. et al. Computer modeling of prostate biopsy: tumor size and location — not clinical significance — determine cancer detection // J. Urol. — 1998. — Vol. 159 (Suppl. 4).-P. 1260-1264.

113. Criiey S.R., Partin A. W., Zincke H. et al. Standard PSA reference range versus age-specific PSA reference ranges among men with prostate cancer// Urol. (Baltimore). - 1994.-Vol. 151.-P.449A.

114. Critz FA., Levinson A.K., Williams W.H. et al. Prostate-specific antigen nadir: The optimum level after irradiation for prostate cancer // J.Clin. Oncol. - 1996. - Vol. 14. - P. 2893-2900.

115. Critz F.A. et al. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy // J. Urol. — 1999. —Vol. 161. -P. 1199-1203.

116. Crook J.M., Bahadur Y.A., Bociek R.G. et al. Radiotherapy for localized prostate carcinoma: The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen //Cancer. - 1997. - Vol. 79. - P. 328-336.

117. Crundwell M.C., Cooke P. W., Wallace D.M. Patients tolerance of transrectal ultrasound-guided prostatic biopsy: An audit of 104 cases // Br. J. Urol. - 1999. - Vol. 83. - P. 792-795.

118. Cupp M.R., Bostwick D.G., Myers R.P. et al. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis //J. Urol. - 1995. - Vol. 153. - P. 1543-1548.

119. D'Amico A.V., Whittington R., Malkowicz S.B. et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer // J.Urol. - 1995. - Vol. 154. - P. 131-138.

120. D'Amico A. V., Whittinglon К, Malkowicz S.B. et al An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: Implications on the use of adjuvant therapy // Urology. - 1996. - Vol. 47. - P. 538-547.

121. D'Amico A.V., Whittinglon R., Malkowicz S.B. et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostatespecific antigen failure In patients with clinically organ-confined prostate cancer//J. Clin. Oncol. - 1996. -Vol. 14. - P. 1770-1777.

122. D'Amico A.V., Whittington R. et al. Pretreatment nomogram for prostate specific antigen recurrence after radical prostatectomyor externalbeam radiation therapy for clinically localized prostate cancer // J. Clin Oncol. - 1999. - Vol. 17. - P. 168.

123. D'Amico A.V., Whittington R., Malkowicz S.B. et al. Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer// Urology. - 2000. - Vol. 55. - P. 572-577.

124. Dalkin B.L., Ahmann F.R., Kopp J.B. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma // J. Urol. (Baltimore). - 1993. - Vol. 150. - P. 1837.

125. Dalkin B.L., Ahmann F., Southwick P. et al. Derivation of normalprostate specific antigen (PSA) level by age // J. Urol. (Baltimore). - 1993.-Vol. 149.-P. 413A.

126. Daneshgari K, Taylor G.D., Miller G.J. et al. Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies // Urology. — 1995. — Vol. 45 (Suppl. 4). - P. 604-609.

127. Daniels G.F. Jr, McNeal J.E., Stamey T.A. Predictive value of contralateral biopsies in unilaterally palpable prostate cancer // J. Urol. —1992. - Vol. 147 (Suppl. 3, Pt. 2). - P. 870-874.

128. Davidson D., Bostwick D.G., Qian J. et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies//J. Urol. - 1995. - Vol. 154. - P. 1295-1299.

129. DeantoniE.P, Crawford E.D., OesterlingJ.E. et al. Age- and racespecific reference ranges for prostate-specific antigen from a large community-based study // Urology. - 1996. - Vol. 48. - P. 234-239.

130. Debiasi F., Londero D., Praturlon S. et al. Longitudinal evaluation of prostate-specific antigen levels // Eur. Urol. — 1996. — Vol. 29. —P. 184-188.

131. De la TailleA., KatzA., Bagiella E. et al. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage // Urology. - 1999. - Vol. 54. - P. 1039-1043.

132. De la Taille A., Bagiella E., Katz A. et al. Perineural invasion in combination with preoperative Gleason score and serum PSA predict stage pT3 disease // Mod. Pathol. - 1999. - Vol. 12. - P. 93A.

133. Demura Т., Watarai Y, Togashi M. et al. Measurement of prostate specific antigen and gammaseminoprotein ratio: a new means of distinguish benign prostatic hyperplasia and prostate cancer // J. Urol. —1993. - Vol. 150 (Suppl. 5, Part 2). - P. 1740-1745.

134. Demura T.,ShinoharaN, TanakaM. et al. The proportion of free to total prostate specific antigen: A method of detecting prostate carcinoma//Cancer. - 1996.-Vol. 77. - P. 1137-1143.

135. Desgrandchamps F., Meria P., Irani J. et al. The rectal administration of lidocaine gel and tolerance of transrectal ultrasonography-guided biopsy of the prostate: A prospective randomized placebo-controlled study// Br. J. Urol. - 1999. - Vol. 83. - P. 1007-1009.

136. Diamandis E.P., Yu II. Editorial: new biological functions of prostate specific antigen? // J. Clin. Endocrinology and Metabolism. —1995. - Vol. 80 (Suppl. 5). - P. 1515-1517.

137. Djavan В., Zlotta A., Remzi M. et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 men//J. Urol.-2000.-Vol. 163. - P. 1144-1149.

138. Djavan В., Zlotta A.R., Ekane S. et al. Is one set of sextant biopsies enough to rule out prostate cancer? A prospective study on the influence of transition and total prostate volumes on prostate cancer yield //Eur. Urol. - 2000. - Vol. 38. - P. 218-224.

139. Djavan В., Mazal P., Zlotta A. et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European prostate cancer detection study // Prostate. — 2001.-Vol. 47 (Suppl. 2). -P. 111-117.

140. Djavan В., Ravery V., Zlotta A. et al. Pathological features and significance of prostate cancer detected on first, second, third and fourth repeat biopsy: when should we stop? // Eur. Urol. - 2001. - Vol. 39 (Suppl. 5). - P. 28.

141. Djavan В., Ravery V., Zlotta A. et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? // J. Urol. - 2001. -Vol. 166. - P. 1679-1683.

142. Djavan В., Waldert M., Zlotta A. et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: Results of a prospective European prostate cancer detection study // J. Urol. - 2001. - Ш. 166. - P. 856-860.

143. Dorr V.J., Williamson S.K., Stephens R.L. Evaluation of prostate-specific antigen as a screening test for prostate cancer // Arch. Intern. Med. - 1993. -Vol. 153. - P. 2529-2537.

144. Douville P., Cembrowski G. DRE-PSA data revisited: PSA sampling should precede DREs // Arch. Intern. Med. - 1996. - Vol. 156. -P. 1352.

145. Durkan G.C., Sheikh N., Johnson P. et al. Improving prostate cancer detection with an extended-core transrectal ultrasonography-guided prostate biopsy protocol // BJU Int. - 2002. - Vol. 89. - P. 33-39.

146. Dutkiewicz S., Witeska A., Stepieri К Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH) // Int. Urol. Nephrol. - 1995. -Vol. 27. - P. 763-768.

147. Dutkiewicz S., Stepieri K, Witeska A. Effect of digital rectal examination on plasma prostate-specific antigen (PSA) // Int. Urol. Nephrol. - 1996. - Vol. 28. - P. 211-214.

148. Egan A.J., Bostwick D.G. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis // Am. J. Surg. Pathol. — 1997. — Vol. 21. - P. 1496-1500.

149. EganA.J., Bostwick D.G. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks independent significance // Lab. Invest. - 1997. - Vol. 76. - P. 421.

150. Egawa S., Ohori M., Uchida T. et al. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan // Cancer. - 1997. - Vol. 79. - P. 90-98.

151. Egevad L., Frimmel IL, Mattson S. et al. Biopsy protocol stability in a three-dimensional model of prostate cancer: changes in cancer yield after adjustment of biopsy positions // Urology. — 1999. — Vol. 54 (Suppl. 5). - P. 862-868.

152. Egevad L., Frimmel H., Norberg M. et al. Three-dimensional computer reconstruction of prostate cancer from radical prostatectomy specimens: Evaluation of the model by core biopsy simulation //Urology. - 1999. - Vol. 53. - P. 192-198.

153. Eisenberger M.A., Nelson W.G. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution // J. Nat. Cancer. Inst. - 1996. - Vol. 88. - P. 779-781.

154. Elgamal A.A.A., Comillie F.J., Van PoppelH.P. et al. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage Tic prostate cancer // J. Urol. (Baltimore). - 1996. - Vol. 156. - P. 1042-1047.

155. Elgamal A.A.A., Ectors N.L., Sunardhiwidyaputra S. et al. Detection of prostate specific antigen in pancreas and salivary glands: A potential impact on prostate cancer overestimation // J. Urol. (Baltimore). - 1996. - Vol. 156. - P. 464-468.

156. Elgamal A., Baert L. The periurethral glands do not significantly influence the serum prostate specific antigen concentration // J. Urol. (Baltimore). - 1997. - Vol. 157. - P. 269.

157. Ellis W.J., Brawer M.K. The significance of isoechoic prostatic carcinoma // J. Urol. - 1994. - Vol. 152. - P. 2304-2307.

158. Ellis W.J., ChetnerM., PrestonS. et al. Diagnosis of prostatic carcinoma: the yield of serum PSA, DRE and TRUS // J. Urol. - 1994. -Vol. 152.-P. 1520-1525.

159. Ellis W.J., Brawer M.K. Repeat prostate needle biopsy: Who needs it? // J. Urol. - 1995. - Vol. 153. - P. 1496.

160. Ellis W.J. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies // J. Urol. (Baltimore). — 1996. — Vol. 156. —P. 431.

161. Epstein J.I., Walsh P. C, Camichael M. et al. Pathologic and clinical findings to predict tumor extent on nonpalpable (stage Tic) prostate cancer//JAMA. - 1994. - Vol. 271 (Suppl. 3). - P. 368-374.

162. Epstein J.I., Grignon D.J., Humphrey P. A. et al. Interobserver reproducibility in the diagnosis of intraepithelial neoplasia // Am. J. Surg. Pathol. - 1995. - Vol. 19. - P. 873-876.

163. Epstein J.I. The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens // Cancer. — 1996. — Vol. 78 (Suppl. 2). - P. 350-356.

164. Epstein J.I., Walsh P. C, SauvageotJ. et al. Use of repeat sextantand transition zone biopsies for assessing extent of prostate cancer // J.Urol. - 1997. - Vol. 158. - P. 1886.

165. Epstein J.I., ChanD.W., Sokoll L.J. et al. Nonpalpable stage Tic prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings // J. Urol. — 1998. —Vol. 160. - P. 2407.

166. Epstein J.I. Are you getting the maximum diagnostic and prognostic information from your prostate needle biopsies? // Cont. Urol. -1999, Apr. - P. 106-118.

167. Eskew L.A., Bare R.L., McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate // J. Urol. - 1997. - Vol. 157. - P. 199-203.

168. Eskew L.A., Woodruff R.D., Bare R.L. et al. Prostate cancer diagnosed by the 5 region biopsy method is significant disease // J. Urol. -1998. - Vol. 160. - P. 794-796.

169. Espana F., Martinez M., Sanchez-Cuenca J. et al. Prostate-specific antigen and its complexes with alpha(l)-antichymotrypsin in the plasma of patients with prostatic disease // Europ. Urol. - 1996. - Vol. 30. -P. 512-518.

170. Esposti P.L. Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biopsy // Scand. J. Urol. Nephrol. - 1971. -Vol. 5. - P. 199-209.

171. Etzioni R., Shen Y., Petteway J.C. et al. Age-specific prostate-specific antigen: A reassessment // Prostate. — 1996. — Suppl. 7. — P. 70—77.

172. Feneley M.R., McLean A., Webb J.A.W. et al. Age corrected prostate specific antigen in symptomatic benign prostatic hyperplasia // J.Urol. (Baltimore). - 1994. - Vol. 151. - P. 312A.

173. Ferguson R.S. Prostatic neoplasms: their diagnosis by needle puncture and aspiration // Am. J. Surg. - 1930. - Vol. 9. - P. 507-551.

174. Figg W.D., Ammerman K, Patronas N. et al. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer // Cancer. Invest. -1996. -Vol. 14. - P. 513-517.

175. Filella X., Molina R., Ballesta A.M. et al. Value of PSA (prostatespecific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study // Eur. J. Cancer. — 1996. -Vol. 32A - P. 1125-1128.

176. Fink K.G., Lumper W., Hutarew G. et al. A single 10 core prostate biopsy is superior to two sets of sextant prostate biopsy // Eur. Urol. -2000. - Vol. 37 (Suppl. 2). - Abstract. 293.

177. Fink KG., Hutarew G., Esterbauer B. et al. Prostate cancer detection with two consecutive sets often core biopsies // Eur. Urol. — 2001. —Vol. 39 (Suppl. 5). - P. 29.

178. Fink KG., Hutarew G., Fytel A. et al. Comparison of prostate biopsy outcome by using either 19 or 33 mm cutting length. Materials of Central European Meeting (European School of Urology). - 2001. - P. 137.

179. Fowler J.E., Condon M.A., Terrell EL. Cancer diagnosis with prostate specific antigen greater than 10 ng/ml and negative peripheral zone prostate biopsy // J. Urol. (Baltimore). - 1996. - Vol. 156. -P. 1370-1374.

180. Freitas J.E., Gilvydas R., Ferry J.D., Gonzalez. J.A. The clinical utility of prostate specific antigen and bone scintigraphy in prostate cancer follow-up //J. Nucl. Med. - 1991. - Vol. 32. - P. 1387-1389.

181. Flicker J. Ejaculation raises PSA levels // Lancet. - 1996. -Vol. 347. - P. 1250.

182. Froschermaier S.E., Pilarsky СР., Wirth M.P. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma // Urology. - 1996. - Vol. 47. -P. 525-528.

183. GarberSJ., GoldenbergS.L., Cooperberg P.L. et al. Systemic transrectal ultrasound-guided biopsy of the prostate //J. Can. Assoc. Radiol. —1994. - Vol. 45. - P. 387-390.

184. Garcia G., Chevallier D., Amiel J. et al. Etude prospective comparant la biopsie trans-trectale echoguidee et la biopsie trans-perineale guidee au doigt dans le diagnostic du cancer de la prostate // Prog. Urol. —2001.-Vol. 11.-P. 40-44.

185. Geary E.S., Stamey T.A. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a hybritech prostate specific antigen of 4 to 10 ng/ml // J. Urol. (Baltimore). - 1996. -Vol. 156.-P. 1056-1058.

186. Gibbons R.P. Prostate specific antigen detected prostate cancer // J. Urol. (Baltimore). - 1996. -Vol. 155. - P. 827.

187. Gilliland F.D., Hunt W.C., Key C.R. Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigenera// Urology. - 1996. -Vol. 48. - P. 67-71.

188. Gleave M.E., Coupland D., Drachenberg D. et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer // Urology. — 1996. — Vol. 47 —P. 708-712.

189. Golab A., Slojewski M., Gliniewicz B. Results of prostate biopsy with reference to digital rectal examination, prostate specific antigen and transrectal ultrasonography // Materials of Central European Meeting (European School of Urology). - 2001. - P. 139.

190. Good СВ., Whittle J., Macpherson D.S. et al. DRE-PSA data revisited: PSA sampling should precede DREs // Arch. Intern. Med —1996. -Vol. 156. - P. 1352-1353.

191. Goto Y., Ohori M., Arakawa A. et al. Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies//J. Urol. - 1996. -Vol. 156.-P. 1059-1066.

192. Graefen M., Hammerer P., Michl U. et al. incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy // Urology. - 1998. - Vol. 51. - P. 437-442.

193. Graefen M., Noldus J., Pichlmeier U. et al. Early-prostate specific antigen relapse after radical retropubic prostatectomy: Prediction on the basis of preoperative tumor characteristics // Eur. Urol. — 1999. — Vol. 36.-P. 21-30.

194. Graves H.C.B. Standardization of immunoassays for prostate-specific antigen. A problem of prostate-specific antigen complexation or a problem of assay design?//Cancer. - 1993. -Vol. 72. -P. 3141-3144.

195. Green C.J., Hadorn D., Basset: K. et al. Prostate-Specific Antigen in the Early Detection of Prostate Cancer. — Vancouver, British Columbia. — British Columbia Office of Health Technology Assessment. — 1993.

196. Grossk/aus D., Shappetl S., Gautam S. et al. Ratio free-to-total prostate specific antigen correlates with tumor volume in patient with increased prostate specific antigen // J. Urol. — 2001. — Vol. 165. — P. 455-458.

197. Haggman M.J., Macoska J.A., Wojno K.J. et al. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues//J. Urol. - 1997. -Vol. 158. - P. 12-22.

198. Hamm M., Semjonow A., Ralhert P. Storage stability of prostate-specitic antigen // Aktuel. Urol. - 1996. - Vol. 27. - P. 141-145.

199. Hammerer P., Huland H., Sparenberg A. et al. Digital rectal examination, imaging, and random biopsies in identifying lymph-node-negative prostatic carcinoma // Eur. Urol. — 1992. — Vol. 22. — P. 281-287.

200. Hammerer P., Huland H. Systemic sextant biopsies in 651 patients referred for prostate evaluation // J. Urol. — 1994. — Vol. 151. — P. 99-102.

201. Hammerer P.G., McNeal J.E., Stamey T.A. Correlation between serum PSA levels and the volume of the individual glandular zones of the human prostate//J. Urol. (Baltimore). - 1995. - Vol. 155.

202. Hammerer P.G., Graefen M., Palissar J. et al. ESU Course «TRUS and biopsy — practical aspects». — Geneva, 2001. — Vol. 2. —P. 36-42.

203. Harewood L.M., Cleeve L.K. Carcinoma of the prostate: Improved diagnosis by specific biopsy of the peripheral zone // J. Urol. —1996.-Vol. 155.-P. 424A.

204. Harndy F.C. Detection of circulating prostate-specific antigen-positive cells in patients with prostate cancer by flow cytometry and reverse transcription polymerase chain reaction // Brit. J. Cancer. — 1996. — Vol. 74. - P. 400-405.

205. Harris C.H., Dalkin B.J., Martin E. et al. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4 ng/ml. or less//J. Urol. - 1997.-Vol. 157 (Suppl. 5). - P. 1740-1743.

206. Hautmann S.H., Conrad S., Henke R.-P. et al. Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine-needle aspiration cytology // J. Urol. - 2000. - Vol. 163. - P. 1734-1738.

207. Heidenreich A., Vorreuther R., Neubauer S. et al. The influence of ejaculation on serum levels of prostate specific antigen // J. Urol. (Baltimore). - 1997. - Vol. 157. - P. 209-211.

208. Hendrikx J.M., Sedelaar M., Vijverberg L.M. et al. ESU Course «TRUS and biopsy - practical aspects». - 2001. - Vol. 2. - P. 1-14.

209. Higashihara E., Nutahara K., Kojima M. et al. Significance of serum free prostate specific antigen in the screening of prostate cancer //J. Urol. (Baltimore). - 1996. -Vol. 156. - P. 1964-1968.

210. Hodge K.K., McNealJ.E., Stamey T.A. Ultrasound-guided transrectal core biopsies of the palpably abnormal prostate // J. Urol. - 1989. - Vol. 142. - P. 66-70.

211. Hodge K.K., McNealJ.E., Terris M.K. et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate//J. Urol. - 1989.-Vol. 142. - P. 71-74.

212. Hollabaugh R.S.Jr, Dmochowski R.R., Steiner M.S. Neuroanatomy of the male rhabdosphincter // Urology. - 1997. - Vol. 49. - P. 426.

213. Horninger W., ReissiglA., Fink К et al. Results of a prospective randomized study comparing the prostate cancer detection rates in PSA screening volunteers undergoing 10 vs. 14 transrectal ultrasound guided biopsies//J. Urol. - 1998. -Vol. 159 (Suppl.). - P. 180.

214. HulandH., Hammerer P., Henke R. P. et al. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies // J. Urol. - 1996. -Vol. 155.-P. 1344-1347.

215. Huland H. // ESU Course «Best treatment for localized prostate cancen. - Geneva, 2001. - Vol. 23. - P. 1-8.

216. Humphrey P. A., Keetch D.W., Smith D.S. et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening // J. Urol. (Baltimore). - 1996.-Vol. 155.-P. 816-820.

217. Huncharek M., Muscat J. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer // Abdom. Imaging. — 1996. — Vol. 21. — P. 364-367.

218. Irani J., Millet C, Levillain P. et al. Serum-to-urinary prostate-specific antigen ratio: A potential means of distinguishing benign prostatic hyperpiasia from prostate cancer // Eur. Urol. — 1996. — Vol. 29. — R 407-412.

219. Irani J., Millet C, Levillain P. et al. Serum-to-urinary prostate-specific antigen ratio: Its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 NG/ML // J. Urol. (Baltimore). - 1997. - Vol. 157. - P. 185-188.

220. Irani J., FournierF., Bon D. et al. Patient tolerance of transrectal ultrasound-guided biopsy of the prostate // BJU. - 1997, Apr. - Vol. 79 (Suppl. 4). - P. 608-610.

221. Isen K., Kupeli В., Sinik Z. et al. Antibiotic prophylaxis for tran srectal biopsy of the prostate: a prospective randomized study of the prophylactic use of single dose oral fluoroquinolone versus trimethoprim-sulfamethoxazole // Int. Urol. Nephrol. - 1999. - Vol. 31 (Suppl. 4). - P. 491-495.

222. Isikay L., Yaman O., Bozlu M. et al. Prostate-specific antigen density: The role in benign prostate hyperpiasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma // Int. Urol. Nephrol. - 1995. - Vol. 27. - P. 757-762.

223. Issa M.M., Bux S., Chun T. et al. A randomized prospective trial of intrarectal lidocaine for pain control during transrectal prostate biopsy: the Emory University experience // J. Urol. — 2000. — Vol. 164. — P. 397-399.

224. Iwakiri J., Grandbois K, Wehner N. et al. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands // J.Urol. (Baltimore). - 1993. - Vol. 149. - P. 783-786.

225. Jacobsen S.J., Guess H.A., Oesterling J.E. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves//J. Urol. (Baltimore). — 1996. —Vol. 155. - P. 1395-1396.

226. Jacobsen S.J., Bergstra/h E.J., Guess H.A. et al. Predictive properties of serum prostate-specific antigen testing in a community-based setting//Arch. Intern. Med. - 1996. -Vol. 156. - P. 2462-2468.

227. Jung K, Lein M., Henke W. et al. Isoforms of prostate-specific antigen in serum: A result of the glycosylation process in dysplastic prostatic cells? // Prostate. - 1996. - Vol. 29. - P. 65-66.

228. Jung K, Meyer A., Lien M. et al. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patient with prostate cancer from those with chronic inflammation of the prostate //J. Urol - 1998 - Vol. 159 (Suppl. 5). - R 1595-1598.

229. Junker R., Brandt В., Semjonow A. et al. Measurement of prostate specific antigen: No advantage to ultrasensitive assays? // J. Nat Cancer. Inst. - 1996. - Vol. 88. - P. 1594-1595.

230. Kadayifci A., Benekli M., Simsek H. et al. Prostatic acid phosphatase and prostate specific antigen in liver disease // Int Urol Nephrol. - 1996. - Vol. 28. - P. 67-72.

231. Kadmon D., Weinberg A.D., Williams R.H. el al. Pitfalls in interpreting prostate specific antigen velocity//J. Urol (Baltimore) -1996 - Vol. 155.-P. 1655-1657.

232. Kamoshida S., Tsutsumi Y. Extraprostatic localization of prostatic acid phosphatase and prostate specific antigen: distribution in cloacogenic glandular epithelium and sex dependent expression in human anal gland//Hum. Pathol. - 1990. - Vol. 21. - R 1108-1 111.

233. Karakiewkz PL, Aprikian A.G., MeshrefA. W. el al. Computer-assisted comparative analysis of four-sector and six-sector biopsies of the prostate // Urology. - 1996. - Vol. 48. - P. 747-750.

234. Karakiewkz P. L, Bazinet M., Aprikian A.G. et al. Outcome of sextant biopsy according to gland volume//Urology - 1997 _ Vol 49 -P. 55-59.

235. Karazanashvili G., Managadze L. Prostate-specific antigen value change after antibacterial therapy of prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4-10 ng/ml and nonsuspicious results of digital rectal examination // Eur. Urol. - 2001. - Vol. 39. - P. 538-543.

236. Katz A.E., Devries G.M., Benson M.C. et al. The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy // Urol Clin N. Amer. - 1996. - Vol. 23. - P. 541.

237. Keetch D.W., McMurtry J.M., Smith D.S. et al. Prostate specificantigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies // J Urol. - 1996. - Vol. 156 (Suppl. 2, Part 1). - P. 428-431.

238. Keetch D.W., Catalona W.J., Smith D.S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values //J. Urol. - 1997.-\Ы. 151.-P. 1571-1574.

239. Keisch M.E., Perez C.A, Grigsby PWet al. Preliminary report on 10 patients treated with radiotherapy after radical prostatectomy for isolated elevation of serum PSA levels // Int. J. Radiat. Oncol. Biol. Phys. — 1980. -Vol. 19. - P. 1503-1506.

240. KibelA.S., Krithivas K, Shamel L.B. et al. Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma// Urology. - 1996. - Vol. 48. - P. 741-746.

241. Kirollos M.M. Prostate-specific antigen and ageIs there a correlation? And why does it seem to vary? // Europ. Urol. - 1996. - Vol. 30. - P. 296-300.

242. Kirschenbaum A., Pacheco E., Schuval B.J. et al. Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy // World J. Urol. - 1996. - Vol. 14. - P. 360-362.

243. Klee G.G., Dodge L.A., Zincke H. et al. Measurement of serum prostate-specific antigen concentration using IMx prostate specific antigen assay//J. Urol. (Baltimore). - 1994. -Vol. 151. - P. 94.

244. Klein E.A. Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies? // J. Urol. — 1996. — Vol. 156. - P. 443-444.

245. Klein E.A., Zippe CD. Editorial. Transrectal ultrasound-guided prostate biopsy — defining a new standard // J. Urol. - 2000. — Vol. 163. —P. 179-180.

246. Kleer E., Larsen-Keller J.J., Zincke H. Ability of preoperative serum prostate specific antigen value to predict pathological stage and DNA ploidy: influence of clinical stage and tumor grade // Urology. — 1993.-Vol. 40. -P. 207.

247. Kline T.S., Kelsey D.M., Kohler F.P. et al. Prostatic carcinoma and needle aspiration biopsy // Am. J. Clin Pathol. - 1977. - Vol. 67. - P. 131-133.

248. Knight M., Amling C.L., Karnes J. et al. Diagnosis and treatment of prostate cancer in patients after rectal resection // J. Urol. — 2000. —Vol. 163 (Suppl. 4).-P. 91.

249. Knobloch R. von, Weber J., Varga Z. et al. Bilateral fineneedle administered local anaesthetic nerve block for pain control during TRUS-guided multi-core prostate biopsy: a prospective randomized trial // Eur. Urol. - 2002. - Vol. 41. - P. 508-514.

250. Kojima Y, Nonomura N., Nose T. et al. Transition zone biopsy in the detection of prostate cancer // Eur. Urol. - 2000. - Vol. 37 (Suppl. 6). - P. 675-679.

251. Komatsu K, Wehner N., Presligiacomo A.F. et al. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population // Urology. — 1996. — Vol. 47. — P. 343—346.

252. Komoi K, Troncoso P., Babaian R.J. Strategy for repeat biopsy in patients with high grade PIN // J. Urol. - 2000. - Vol. 163. - P. 819-823.

253. Koutani A., Lechevallier E., Coulange С Prostate specific antigen// Ann. Urol. - 1996. - Vol. 30. - P. 257-261.

254. Kucuk O., Demirer Т., Gilman-Sachs A. et al. Intratumor heterogeneity of DNA ploidy and correlations with clinical stage and histologic grade in prostate cancer // J. Surg. Oncol. — 1993. — Vol. 54 (Suppl. 3). — P. 171-174.

255. Kupelian P., Katcher J., Levin H. et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer // Urology. — 1996.-Vol. 48.-P. 249-260.

256. Labrie F., Dupont A., Suburu R. et al. Serum prostate-specific antigen as a prescreening test for prostate cancer // J. Urol. (Baltimore). — 1992. - Vol. 147. - P. 846-852.

257. Lange P. H., Ercole C.J., Lightner DJ. et al. The value of serum prostate specific antigen determination before and after radical prostatectomy//J. Urol. - 1989. - Vol. 141. - P. 873.

258. Lawrence G. The central role of prostate specific antigen in diagnosis and progression of prostate cancer // J. Urol. (Baltimore). — 1996. — Vol. 156. - P. 484.

259. Lee F., TorpPedersen S., Littrup P.J. et al. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen // Radiology. - 1989. - Vol. 170. - P. 29-32.

260. Lee C, Keefer M., Zhao Z. W. et al. Demonstration of the role of prostate-specific antigen in semen liquefaction by two-dimensional electrophoresis // J. Androl. - 1989. - Vol. 10. - P. 432-438.

261. Lee W.R., Hanlon A.L., Hanks G.E. Prostale specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival// Urol. (Baltimore). - 1996.-Vol. 156. - P. 450-453.

262. Leinonen J., Livgren Т., Vornanen T. et al. Double-label time resolved immunofluorometric assay of prostate-specific antigen and to its complex with al-antichymotrypsin // Clin. Chem. — 1993. — Vol. 39. — P. 2098-2103.

263. Leinonen J., Zhang W.M., Stenman U.H. Complex formation between PSA isoenzymes and protease inhibitors // J. Urol. (Baltimore). — 1996. -Vol. 155. - P. 1099-1103.

264. Lemer S.E., Jacobsen S.J., Lilja H. et al. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate // Urology. — 1996. — Vol. 48. — P. 240-248.

265. Lemer S.E., Seay T.M., Blute M.L. et al. Prostate specific antigen detected prostate cancer (clinical stage TIC): An interim analysis // J. Urol. (Baltimore). - 1996. - Vol. 155. - P. 821-826.

266. Leshevalier E. La ponction biopsie de la prostate // Prog. Urol. — 1996.-Vol. 6.-P. 515-518.

267. Lessels A.M., Burnett R.A., Howatson S.R. et al. Observer variability in the histopathological reporting of needle biopsy specimens of the prostate // Hum. Pathol. - 1997. - Vol. 28. - P. 646-649.

268. Levine M.A., Ittman M., MelamedJ. et al. Two consecutive sets of transrectal ultrasound-guided sextant biopsies of the prostate for the detection of prostate cancer//J. Urol.- 1998.-Vol. 159.- P. 471-476.

269. Lightner D.J., Lange P. H, Reddy P. K, Moore L. Prostate specific antigen and local recurrence after radical prostatectomy // J. Urol. — 1990. - Vol. 144. - P. 921-926.

270. Lilja H., Christensson A., Dahlin U. el al. Prostate-specific antigen in human serum occurs predominantly in complex with alpha-antichymotrypsin//Clin. Chem. - 1991. -Vol. 37. - P. 1618-1625.

271. Lilja H. Significance of different molecular forms of serum PSA: the free, noncomplexed to alpha-1-antichymottrypsine // J. Urol. — 1993. - Vol. 20 (Suppl. 4). - P. 681-686.

272. Lilja H., Bjork Т., Abrahamsson P.A. et al. Improved separation between normals, benign prostatic hyperpiasia (BPH) and carcinoma of the prostate (CAP) by measuring free (F), complexed (C) and total (T) concentrations of prostate specific antigen (PSA) // J. Urol. (Baltimore). - 1994. - Vol. 151. - P. 400A.

273. LindenK.A., Kabalin J.N., Terris M.K. Bacteriemia and bacteriuria after transrectal ultrasound-guided prostate biopsy // J. Urol. — 2000. - Vol. 164. - P. 76-80.

274. Loch Т., McNeal J.E., Stamey T.A. Interpretation of bilateral positive biopsies in prostate cancer // J. Urol. — 1995. — Vol. 154. — P. 1078-1083.

275. Lodding P., Aus G., Bergdahl S. et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml prostate specific antige // J. Urol. - 1998. - Vol. 159 (Suppl. 3). -P. 899-903.

276. Longhi S., Scarpone P., Pansadoro A. et al. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen // J. Urol. - 2001. - Vol. 166. - P. 845-850.

277. Luderer A.A., Chen Y, Soriano Т.Е. et al. Measurement of the proportion of free to total prostate-specific antigen improves the diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen // Urology. - 1995. - Vol. 46. - P. 187-194.

278. Lui P.D., Terris MX., McNeal J.E. et al. Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer //J. Urol. - 1995. - Vol. 153. - P. 1000-1003.

279. Lundwall A., Lilja H. Molecular cloning of human proslate specific antigen DNA// FEBS Lett. - 1987. -Vol. 214. - P. 317-322.

280. Lundwall A. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein // Biochem. Biophys. Res. Com. —1989.-Vol. 161.-P. 1151-1159.

281. Madersbacher S., Mian C, Maier U. et al. Validation of a 10-minute dipstick test for serum prostate-specific antigen // Eur. Urol. —1996. - Vol. 30. - P. 446-450.

282. Malavaud В., VillersA., Ravery V. et al. Role ofpreoperative positive apical biopsies in the prediction of specimen-confined prostate cancer after radical retropubic prostatectomy: a multi-institutional study // Eur. Urol. - 2000. - Vol. 37. - P. 281-288.

283. Malkowicz S.B. Serum prostate-specific antigen elevation in the post-radical prostatectomy patient // Urol. Clin. N. Amer. — 1996. — Vol. 23. - P. 665.

284. Manseck A., Guhr K., Hakenberg O. W. et al. Are transition zone biopsies necessary when doing rebiopsies on patients with elevated PSA after benign result of a first biopsy? // Eur. Urol. - 2001. - Vol. 39 (Suppl. 5). - P. 30.

285. Marley G.M., Miller M.C., Kalian M. W. et al. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia // Urology. — 1996. - Vol. 48 (Suppl. 1). - P. 16-22.

286. Mattfeld Т., Kestler H.A., Hautmann R. et al. Prediction of postoperative prostatic cancer stage on the basis of systematic biopsies using two types of artificial neural networks // Eur. Urol. — 2001. — Vol. 39. — P. 530-537.

287. Matzkin H., PatelJ.P., Altwein J.E. et al. Stage Tla carcinoma of prostate // Urology. - 1994. - Vol. 43 (Suppl. 1). - P. 11-21.

288. Malzkin H., Laufer M., Chen J.Z. et al. Effect of elective prolonged urethral catheterization on serum prostate-specific antigen concentration// Urology. - 1996. - Vol. 48. - P. 63-66.

289. McGee R., Herr J. Human seminal vesicle-specific antigen during semen liquefaction // Biol. Reprod. - 1987. - Vol. 37. - P. 431-439.

290. McLaughlin P.W., SanderH.M., Jiroutek M.R. Prostate-specific antigen following prostate radiotherapy: How low can you go? // J. Clin. Oncol. - 1996. - Vol. 14. - P. 2889-2892.

291. McNeal J.E. The zonal anatomy of the prostate // Prostate —1981. -Vol. 2. -P. 35-40.

292. McNeal J.E., Bostwick D.G. Intraductal dysplasia: a premalignant lesion of the prostate // Hum. Pathol. - 1986. - Vol. 17. - P. 64-71.

293. McNeal J.E. Cancervolume and site of origine of adenocarcinoma of the prostate: Relationship to local and distant spread // Hum Pathol. - 1992. - Vol. 23. - P. 258-266.

294. Meng M. V., Carroll PR. Local therapy for prostate specific antigen recurrence after definitive treatment // Prostate cancer and Prostatic Diseases. - 2001. - Vol. 4. - P. 20-27.

295. Mettlin C, Murphy G.P., Lee F. et al. Characteristics of prostate cancers detected in a multimodality early detecting program // Cancer —1993. - Vol. 72 (Suppl. 5). - P. 1701-1708.

296. Mettlin C, Murphi G.P., Babaian R.G. et al. The results of a five-year early prostate cancer detection intervention // Cancer. — 1996. — Vol. 77. - P. 150-159.

297. Miller P.D., Eardley I., Kirby R.S. Prostate specific antigen and bone scan correlation in staging and monitoring of patients with prostate cancer// Br. J. Urol. - 1992. - Vol. 70. - P. 295-298.

298. Mills S.E., Fowler J.E.J. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens // Cancer. - 1986. - Vol. 57. - P. 346-349.

299. Morgan Т.О., Jacobsen S.J., McCarthy W. F. et al. Age-specific reference ranges for serum prostate-specific antigen in black men // New. Engl. J. Med. - 1996. -Vol. 335. - P. 304-310.

300. Morgan Т.О., McLeod D.G., Leifer E.S. et al. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA// Prostate. - 1996. - Suppl. 7. - P. 58-63.

301. Morote J., Lopez M., Encabo G. et al. Value of routine transition zone biopsies in patients undergoing ultrasound-guided sextant biopsies for the first time // Eur. Urol. - 1999. - Vol. 35. - P. 294-297.

302. Momte J., Encabo G., Lopez M.A. et al. The free-to-total serum prostate specific antigen ratio as a predictor of the pathological features of prostate cancer// Br. J. Urol. - 1999. - Vol. 83. - P. 1003-1006.

303. Morote J, Encabo G., de Torres I.M. Use of Present Free Prostate-Specific Antigen as a Predictor of the pathological features of clinically localized prostate cancer // Eur. Urol. - 2000. - Vol. 38. - P. 225-229.

304. Mostofi F.K., Sesterhenn LA., Davis C.C.J. Prostatic carcinoma: Problems in the interpretation of prostatic biopsies // Hum. Pathol. - 1992.-Vol. 23.-P. 223-241.

305. Moul J. W. Prostate specific antigen only progression of prostate cancer//J. Urol. - 2000. -Vol. 163. - P. 1632-1642.

305. Mrazovac D., Sosic H., Kastelan Z. el al. Digitally guided prostate biopsies compared to those performed under ultrasonographical guidance // Materials of Central European Meeting (European School of Urology). - 2001. - P. 142.

307. Murphy G.P., Barren R.J., Erickson SJ. et al. Evaluation and comparison of two new prostate carcinoma markers: Free-prostate specific antigen and prostate specific membrane antigen // Cancer. — 1996. —Vol. 78.-P. 809-818.

308. Murphy G.P., Tino W.T., Holmes E.H. et al. Measurement of prostate-specific membrane antigen in the serum with a new antibody // Prostate. - 1996. - Vol. 28. - P. 266-271.

309. Murphy G., Tjoa В., Ragde H. et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous cells pulsed with HLA-A0201 specific peptides from prostate-specific membrane antigen // Prostate. - 1996.-Vol. 29.-P. 371-380.

310. Murray C.L., Jolitz G., Bushhouse S. et al. The fall in incidence of prostate carcinoma: On the down side of a prostate specific antigen induced peak in incidence - Data from the Utah cancer registry //Cancer. - 1997. - Vol. 79. - P. 188-189.

311. Nadji M., Tabei S.Z., Castro A. Prostatic specific antigen: an immunohistologic marker for prostatic neoplasms // Cancer. — 1991. — Vol. 48. - P. 1229-1232.

312. Narayan P., FournierG., Gajendran V. et al. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastasis in prostate cancer// Urology. - 1994. -Vol. 44. - P. 519-524.

313. Narayan P., Gajendran V., Taylor S. et al. The role of transrectal ultrasound-guided biopsy-based staging, pre-operative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathological diagnosis in prostate cancer // Urology. — 1995. — Vol. 46. — P. 205-212.

314. Nash P.A., Bruce J.A., Indudham R. et al. Transrectalultrasound-guided prostatic nerve blockade eases systematic needle biopsy of the prostate // J. Urol. - 1996. - Vol. 155 (Suppl. 2). - P. 607-609. 3\5. Naughton C.K., Ornstein D.K., Smith D.S. etal. Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores // J. Urol. - 2000. - Vol. 163. - P. 168.

316. Naughton C.K., Miller D.C., MagerD.E. et al. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection // J. Urol. - 2000. - Vol. 164. - P. 388-392.

317. Naughton C.K., Miller D.C., Yan Y. et al. Impact of transrectal ultrasound guided prostate biopsy on quality of life: a prospective randomized trial comparing 6 versus 12 cores // 5. Urol. - 2001. - Vol. 165 (Suppl. 1).-P. 100-103.

318. Nava L., Montorsi F., Consonni P. et al. Results of a prospective randomized study comparing 6, 12, and 18 transrectal, ultrasound-guided, sextant biopsies in patients with elevated PSA, normal DRE and normal prostatic ultrasound // J. Urol. - 1997. - Vol. 157 (Suppl. 59). - Abstr.226.

319. Nishiya M., Miller G.}., Lookner D.H., Crawford E.D. Prostate specific antigen density in patients with histologically proven prostate carcinoma // Cancer. - 1994. - Vol. 74. - P. 3002-3009.

320. Noguchi M., Stamey T.A., McNeal J.E. et al. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer//J. Urol. - 2001. -Vol. 166. - P. 104-110.

321. Norberg M., Egevad L., Holmberg L. et al. The sextant protocol for ultrasound-guided core biopsies of the prostate for the detection of prostate cancer// Urology. - 1997. - Vol. 50. - P. 562-566.

322. O'Dov/d G.J., Miller M.C., Orozko R. et al. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis // Urology. - 2000. - Vol. 55 (Suppl. 4). - P. 553-559.

323. Oesterling J.E., Brendler СВ., Epstein J.I. et al. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate //J. Urol. - 1987. - Vol. 138. - P. 92-98.

324. Oesterling J.E., Chan D.W., Epstein J.I. et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy // J. Urol. — 1988. — Vol. 139. - P. 766-772.

325. Oesterling J.E. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate // J Urol. (Baltimore). - 1991. -Vol. 145. - P. 907.

326. Oesterling J.E., BilhartzD.L., TindallD.J. Clinically useful serum markers for adenocarcinoma of the prostate II: // Prostate-specific antigen. American Urological Association Update Series 10. - 1991. - P. 137.

327. Oesterling J.E., Cooner W.H., Jacobsen S.J. et al. Influence of patient age on the serum PSA concentration: an important clinical observation// Urol. Clin. N. Amer. - 1993. -Vol. 20. - P. 671.

328. Oesterling J.E., Jacobsen S.J., Chute C.G. et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges// JAMA. - 1993 - Vol 270 - P. 860-864.

329. Oesterling J.E., Jacobsen S.J., Cooner W.H. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older//J. Urol. - 1995. -Vol. 153. -P. 1160-1163.

330. Oesterling J.E. Age-specific reference ranges for serum PSA //New Engl. J. Med. -1996. - Vol. 335. - P. 345-346.

331. Oesterling J.E., Tekohamdani A.H., Martin S.K. et al. The periurethral glands do not significantly influence the serum prostate specific antigen concentration // J. Urol. (Baltimore). - 1996. - Vol 155 - P. 1658-1660.

332. Ohori M., Suyama K., Maru N. et al. Prognostic significance of systematic needle biopsy findings // J. Urol. - 2000 - Vol 163 (Suppl. 4). - P. 287.

333. Ohori M., Graefen M., Karakiewicz P.I. el al. Improved predictive accuracy in algorithms including systematic biopsy features // J. Urol -2001. -Vol. 160. -Abstract721.

334. Omstein O.K., Rao G.S., Smith D.S. et al. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels // J. Urol. (Baltimore) - 1997 - Vol. 157.-P. 195-198.

335. Oyen R., Van Popel H., Van de Voorde W. et al. The significance of focal hypoechoic lesions in the peripheral zone of the prostate // J Beige Radiol. - 1995. - Vol. 78. - P. 356-358.

336. Pannek J., Subong E.N.P., Jones K.A. et al. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer// Urology. — 1996 - Vol 48 (Suppl.).-P. 51-54.

337. Pareek G., Armenakas N.A., Fracchia J.A. Periprostatic nerve blockade for transrectal ultrasound guided biopsy of the prostate: A randomized, double-blind, placebo-controlled study // J. Urol. - 2001. -Vol. 166. - P. 894-897.

338. Partin A.W., Pound C.R., Clemens J.Q. et al. Serum PSA after anatomic radical prostatectomy // Urol. Clin. North. Am. — 1993. — Vol. 20.-P. 713-725.

339. Partin A. W., Yoo J., Carter H.B. et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer // J. Urol. — 1993. — Vol. 150. — P. 110-114.

340. Partin A. W., Pearson J.D., Landis P.K. et al. Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases // Urology. — 1994. — Vol. 43. — P. 649-656.

341. Partin A. W., Carter H.B. The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer// Urol. Clin. N. Amer. - 1996. - Vol. 23. - P. 531.

342. Partin A.W., Catalona W.J., Southwick PC. et al. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume and age // Urology. — 1996. — Vol. 48 (Suppl.). - P. 55-61.

343. Partin A. W., Oesterling J.E. The clinical usefulness of percent free-PSA// Urology. - 1996. - Vol. 48 (Suppl.). - P. 1-3.

344. Partin A. W., Piantadosi S., Subong E.N.P. et al. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy // Prostate. - 1996. - Suppl. 7. - P. 35-39.

345. Partin A.W., Criley S.R., Subong E.N.P. et al. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis //.J. Urol. (Baltimore). - 1996. -Vol. 155. - P. 1336-1339.

346. Partin A.W., Kattan M.W., Subong M.S. et al. Combination of prostate-specific antigen, clinical stage end Gleason score to predict pathological stage of localized prostate cancer: a multiinstitutional update //JAMA. - 1999. - Vol. 277. - P. 1445-1451.

347. Partin A.W., Mangold L.A., Lamm D.M. et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium // Urology. - 2001. - Vol. 58. - P. 843-848.

348. Pearson J.D., Luderer A.A., Metier EJ. et al. Longitudinal analysis of serial measurements of free and total PSA among men with and with out prostatic cancer // Urology. - 1996. - Vol. 48 (Suppl.). - P. 4-9.

349. Peller P.A., Young D.C., Marmaduke D.P. et al. Sextant prostate biopsies: a histopathologic correlation with radical prostatectomy specimens // Cancer. - 1995. - Vol. 75 (Suppl. 2). - P. 530-538.

350. Peters J.L., Thompson A.C., McNicholas T.A. et al. Increased patient satisfaction from transrectal ultrasonography and biopsy under sedation// BJU Int. - 2001. - Vol. 87. - P. 827-830.

351. Peyromaure M., Ravery V, MessasA. et al. Pain and morbidity of an extensive prostate 10-biopsy protocol: a prospective study in 289 patients // J. Urol. - 2002. - Vol. 167. - P. 218-221.

352. Piironen Т., Petlersson K., Suonpaa M. et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples // Urology. — 1996. - Vol. 48 (Suppl.). - P. 81-87.

353. Polascik T.J., Oesterling J.E., Partin A. W. Prostate specific antigen: a decade of discovery — what we have learned and where we are going//J. Urol. - 1999. - Vol. 162. - P. 193-306.

354. Pollack A., Lank/ord S., Zagars G.K. et al. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy// Cancer. - 1996. - Vol. 77. - P. 1515-1523.

355. Prange W., Erbersdobler A., Hammerer P. el al. Significance of high-grade prostatic intraepithelial neoplasia in needle biopsy specimens // Eur. Urol. - 2001. - Vol. 39 (Suppl. 5). - P. 182.

356. Presti J.C., Hovey R., Carroll P. R. et al. Prospective evaluation of prostate specific antigen and prostate specfic antigen density in the detection of nonpalpable and stage Tic carcinoma of the prostate // J. Urol. (Baltimore). - 1996. - Vol. 156. - P. 1685-1690.

357. Presti J.C. Systematic biopsy of the prostate: 6 just isn't enough // Cont. Urol. -1999, Dec. - P. 11-18.

358. Presti J.C. Jr, Chang J.J., Bhargava V. et al. The optimal systematic prostate biopsy scheme should include eight rather than six biopsies: results of a prospective clinical trial // J. Urol. - 2000. - Vol. 163 - P. 163-167.

359. Prestigiacomo A.F., Stamey T.A. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/ml range in male volun teers//;. Urol. (Baltimore). - 1996. -Vol. 155. - P. 1977-1980.

360. Prestigiacomo A.F., Lilja H, Pettersson K. et al. A comparison of the free fraction of serum prostate specific antigen in men with benign and a cancerous prostates: The best case scenario // J. Urol. (Baltimore). — 1996.-Vol. 156. - P. 350-354.

361. Prestigiacomo A.F., Stamey T.A. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? // J. Urol. (Baltimore). - 1997. - Vol. 157. - P. 189-194.

362. Rabbani F, Stroumbakis N., Kava B.R. et al. Incidence and clinical significance of false-negative sextant prostate biopsies // J. Urol. - 1998. - Vol. 159. - P. 1247-1250.

363. Ravery V., Boccon-Gibod L.A., Dauge-Geffroy M.C. et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent / recurrent detectable PSA after radical prostatectomy// Urology. - 1994. - Vol. 44. - P. 371-376.

364. Ravery V., Schmid H-P., Toublanc M. et al. Is the percentage of cancer in biopsy cores predictive of extra capsular disease in Tl—T2 prostate cancer? // Cancer. - 1996. - Vol. 78. - P. 1079-1084.

365. Ravery V., Szabo J., Toublanc M. et al. A single positive prostate biopsy out of six does not predict a low-volume prostate tumor // Br. J. Urol. - 1996. - Vol. 77. - P. 724-728.

366. Ravery V., BiltebaudT., Toublanc M. et al. Diagnostic value often systematic TRUS-guided prostate biopsies // Eur. Urol. - 1999. - Vol. 35. - P. 298.

367. Ravery V., Goldblatt L., Royer B. et al. Extensive biopsy protocol improves the detection rate of prostate cancer // J. Urol. - 2000. - Vol. 164. - P. 393-396.

368. Ravery V., Fontaine E., Vitlers A. Biopsies prostatiques: modalites techniques et conditions de l'examen // Prog. Urol. - 2000. - Vol. 10. - P. 1271-1276.

369. Ravery V., Chastang C, Toublanc M. et al. Percentage of canceron biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer// Eur. Urol. - 2000. - Vol. 37. - P. 449-455.

370. Raviv G., Zlotta A.P., Janssen Т.Н. et al. Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer//J. Urol. - 1996.-Vol. 156.-P. 1050-1055.

371. Raviv G., Zlotta A. P., Janssen Т.Н. et al. Do prostate specific antigen and PSA density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? // Cancer. - 1996. - Vol. 77 (Suppl. 10). - P. 2103-2108.

372. Recker F, Kwiatkowski U.K., Piironen T. et al. Free-to-total prostate specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patient with prostatism and intermediate PSA levels // Br. J. Urol. - 1998. - Vol. 81 (Suppl. 4). - P. 532-538.

373. Reissigl A., Klocker H., Pointner J. et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening // Urology. - 1996. - Vol. 48 (Suppl.). -P. 62-66.

374. Richardson Т.О., Wojno K.J., Liang L. W. et al. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy // Urology. - 1996. - Vol. 48 (Suppl.). - P. 40-14.

375. Richie J.P., Catalona W.J., Ahmann F.R. et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination // Urology. - 1993. - Vol. 42. - P. 365-374.

376. Riehmann M., Rhodes PR., Cook T.D. et al. Analysis of variation in prostate-specific antigen values // Urology. - 1993. - Vol. 42. - P. 390-397.

377. Rodriguez L. V., Terris M.K Risks and complications of transrectal ultrasound-guided prostate needle biopsy: a prospective study and review of the literature // J. Urol. - 1998. - Vol. 160. - P. 2115-2120.

378. Roehrbprn C.G., PickensG.J., Carmody. Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population // Urology. - 1996. - Vol. 47. - P. 59-66.

379. Roehrborn C.G., Pickens G.J., Sanders J.S. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate-specific antigen levels // Urology. - 1996. - Vol. 47. - P. 347-352.

380. Roehrborn C.G., Gregory A., McConnellJ.D. et al. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology // Urology. — 1996. - Vol. 48 (Suppl.). - P. 23-32.

381. Roehrborn C.G., Boyle P., Gould A.L. et al. Serum prostate specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia // Urology. - 1999. - Vol. 53. - P. 581.

382. Rogatsch H., HittmairA., Reissigl A. et al. Microvessel density incore biopsies of prostatic adenocarcinoma: A stage predictor? // J. Pathol. - 1997. - Vol. 182. - P. 205-210.

383. Rogatsch H., Hominger W., VolggerH. et al. Radical prostatectomy: the value of preoperative, individually labeled apical biopsies // J. Urol. - 2000. - Vol. 164. - P. 754-758.

384. Rogatsh H., Moser P., Volgger H. et al. Diagnostic effect on an improved preembedding method of prostate needle biopsy specimens //Hum. Pathol.-2000.-Vol. 31.-P. 1102-1107.

385. Rogers E., Gurpinar Т., Dillioglugil O. et al. The role of digital rectal examination, biopsy Gleason sum and prostate-specific antigen in selecting patients who require pelvic lymph node dissections for prostate cancer// Brit. J. Urol. - 1996. - Vol. 78. - P. 419-425.

386. Romics I., Wurz, Bach D. The prognostic value of prostate specific antigen in the follow-up of patients after radical prostatectomy // Int.Urol. Nephrol. - 1995. - Vol. 27. - P. 319-324.

387. Ronnett B.M., Carmichael M.J., Carter KB. et al. Does high-grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? // J. Urol. - 1993. - Vol. 150 (Suppl. 2, Pt. 1). - P. 386-389.

388. Rubens D.J., Gottlieb R.H., Maldonado C.E. et al. Clinical evaluation of prostate biopsy parameters: Gland volume and elevated prostate-specific antigen level // Radiology. - 1996. - Vol. 199. - P. 159-163.

389. Ruijter E., van Leenders G, Miller G. et al. Errors in histological grading by prostatic needle biopsy specimens: frequency and predisposing factors // J. Pathol. - 2000. - Vol. 192. - P. 229-233.

390. Safaric L. // ESU Course «TRUS and biopsy - practical aspects» - Geneva, 2001. - Vol. 2. - P. 26-32.

391. Safford H.R., Crawford E.D., Mackenzie S.H. et al. The effect of bicycle riding on serum prostate specific antigen levels // J. Urol. (Baltimore). - 1996. -Vol. 156. - P. 103-105.

392. Saliken J.C., Gray R.R., Donnelly B.J. et al. Extraprostatic biopsy improves the staging of localized prostate cancer // Canad. Assoc. of Radiol. J. - 2000. - Vol. 51. - P. 114-120.

393. Salomon L., Colombel M., Patard JJ. et al. Use of three additional mid biopsies to improve local assessment of prostate cancer in patients with one positive sextant biopsy // Eur. Urol. — 1998. — Vol. 34 (Suppl. 4).-P. 313-317.

394. Salomon L., Colombel M., Patard J.J. et al. Value of ultrasoundguided systematic sextant biopsies in prostate tumor mapping // Eur. Urol. - 1999. - Vol. 35. - P. 289-293.

395. Santucci R.A., Brawer MX. Correlation of PSA and ultrasonography in the evaluation of patients with carcinoma of the prostate // Semin. Urol. - 1994. - Vol. 12. - P. 252-264.

396. Santucci R.A., Lange P.H. Treatment of the patient with a rising PSA (biochemical failure) following radical prostatectomy / In: «Topics in Clinical Urology Medical and Surgical Management of Prostate Cancer». R.G.Middleton (Ed.). - NY: Igaku-Shoin Medical Publishers, 1996.

397. Savage P., Waxman J. PSA and prostate cancer diagnosis // Eur. J. Cancer. - 1996. - Vol. 32A. - P. 1097-1099.

398. SawyerR., Berman JJ., Borkowski A. et al. Prostate-specific antigen in black men // Lancet. - 1996. - Vol. 347. - P. 1329.

399. Scaletscky R., Koch M.O., Gray G.F., Smith J.A. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen //J. Urol. - 1994. -Vol. 152. - P. 129-131.

400. Scardino P.T., Weaver R., Hudson M.A. Early detection of prostate cancer// Hum. Pathol. - 1992. - \bl. 23. - P. 211-222.

401. SchildS.E., WongW.W.,GradoG.L. et al. Radiotherapy for isolated increases in serum prostate specific antigen levels after radical prostatectomy// Mayo Clin. Proc. - 1994. - 1. 69. - P. 613-619.

402. SchmidH.P., McNealJ.E., Stamey T.A. Observations on the doubling time of prostate cancer. The use of serial prostate specific antigen in patients with untreated diseases as a measure of increasing cancer volume // Cancer. - 1993. - Vol. 71. - P. 2031-2040.

403. Schmid H.P., Ravery V., Billebaud T. et al. Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels // Urology. - 1996. - 47. - P. 699-703.

404. Schostak M., Panick M., Goessl С et al. Optimising local anaesthesia for systematic tenfold prostatic biopsy // Eur. Urol. - 2001. - Vol. 39 (Suppl. 5). - P. 181.

405. Schroder F.H., van der Cruijsen-Koeter. et al. Prostate cancer detection at low prostate specific antigen // J. Urol. — 2000. — Vol. 163 (Suppl. 3). - P. 806-812.

406. Schwartz M.K., Smith C, Schwartz D. et al. Evaluation of the Hybritech free (PSA-f) and total PSA (PSA-t) // AACR Annual. Meeting. - 1996.

407. Scott KM., Fanta P., Calaluce R. et al. Diagnostic frozen prostate sextant biopsies: An approach for preserving protein and RNA for additional studies // Prostate. - 2000. - Vol. 44. - P. 296-302.

408. Seaman E. K, Whang I. S., Cooner W. et al. Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate // Urology. - 1994. - Vol. 43. - P. 645-648.

409. Sebo T.J., Bock B.J., Cheville J.C. et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy // J. Urol. — 2000. — Vol. 163.-P. 174-178.

410. Semjonow A., Hamm M., Raltert P. Half-life of prostate specific antigen after radical prostatectomy: the decisive predictor of curative treat ment? // Eur. Urol. - 1992. - Vol. 21. - P. 200-205.

411. Semjonow A., Brandt В., Oberpenning F. et al. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values // Prostate. - 1996. - Suppl. 7. - P. 3-16.

412. Semjonow A., Oberpenning F., Brandt B. et al. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen// Urology. — 1996. — Vol. 48 (Suppl.). — P. 10-15.

413. Seymour H., Perry M.J.A., Lee-Elliot С et al. Pain after transrectal ultrasonography-guided prostate biopsy: the advantages of periprostatic local anaesthesia // BJU Int. - 2001. - Vol. 88. - P. 540-544.

414. ShepherdD., Keetch D.W., Humphrey P. A. et al. Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy //J. Urol. - 1996. - Vol. 156 (Suppl. 2, Pt. 1). - P. 460-463.

415. Sieber P.R., Rommel P.M., Agusta V.E. et al. Antibiotic prophylaxis in ultrasound-guided transrectal prostate biopsy // J. Urol. - 1997. - Vol. 157 (Suppl. 6). - P. 2199-2200.

416. Slavin K. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men // J. Urol. (Baltimore). - 1996. - Vol. 156. - P. 441-442.

417. Smith D.S., Catalona W.J. Rate of change in serum prostatic specific antigen levels as a method for prostate cancer detection // J. Urol. — 1994.-Vol. 152.-P. 1163-1167.

418. Smith D.S., Catalona W.J., Herschman J.D. Longitudinal screening for prostate cancer with prostate-specific antigen // JAMA. — 1996. — Vol. 276 (Suppl. 16). - P. 1309-1315.

419. Smith D.S., Carvalhal G.F., Mager D.E. et al. Use of lower prostate-specific antigen cutoffs for prostate cancer screening in black and white men // J. Urol. - 1998. - Vol. 160 (Suppl. 5). - P. 1734-1738.

420. Smitt M.C., Heltzel M. The results of radical prostatectomy at a community hospital during the prostate specific antigen era // Cancer. — 1996. - Vol. 77. - P. 928-933.

421. Soloway M.S., Obek С Periprostatic local anaesthesia before ultrasound guided prostate biopsy // J. Urol. — 2000. — Vol. 163. — P. 172-173.

422. Southwick PC, Catalona W.J., Partin A.W. et al. Prediction of post-radical prostatectomy pathological outcome for stage Tic prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial//J. Urol. - 1999. -Vol. 162. - P. 1346.

423. Speights V.O., Brawn P.N. Serum prostate specific antigen levels in non-specific granulomatous prostatitis // Brit. J. Urol. — 1996. — Vol.77.- P. 408-410.

424. StackhouseG.B., Sesterhenn A., Bauer JJ. et al. P53 and BCL-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy // J. Urol. — 1999. - Vol. 162. - P. 2040-2045.

425. Stamey T.A., Yang N., Hay A.R. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate // N. Engl. J. Med. — 1987.-Vol. 317.-P. 909-916.

426. Stamey T.A., Kabalin J.N., McNeal J.E. et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients // J. Urol. - 1989. - Vol. 141 (Suppl.).-P. 1076-1083.

427. Stamey T.A., Chen Z., Prestigiacomo A. Serum prostate specific antigen binding alpha 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones // J. Urol. (Baltimore). - 1994. - Vol. 152. - P. 1510-1514.

428. Stamey T.A., Prestigiacomo A.F., Chen Z. Standardization of immunoassays for prostate specific antigen: a different view based on experimental observations // Cancer. - 1994. - Vol. 74. - P. 1662-1666.

429. Stamey T.A. Making the most out of six systematic sextant biopsies // Urology. - 1995. - Vol. 45. - P. 2-12.

430. Stamey T.A. Pitfalls in interpreting prostate specific antigen velocity//J. Urol. (Baltimore). - 1996. -Vol. 155. - P. 1657.

431. Stein A., deKernion J.B., Smith R.B. et al. Prostate specific antigen levels after radical prostatectomy in patients with organ-confined and locally extensive prostate cancer // J. Urol. - 1992. - Vol. 147. - p. 942-946.

432. Steinberg D.M., Sauvageot J., Piantadosi S. et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings // Am. J. Surg. Pathol. — 1997. — 21. — P. 566-576.

433. Stenman U.H., Leinonen J., Alfthan H. et al. A complex between prostate-specific antigen and alpha-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer // Cancer. Res. — 1991.-Vol. 51.-P. 222-226.

434. Stenman U.H. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage Tic prostate cancer //, Urol. (Baltimore). - 1996. - Vol. 156. - P. 1047-1048.

435. Stephan C, Jung K, Lein M. et al. The ratio of free to total prostate-specific antigen in serum is correlated to the prostate volume //Int. J. Cancer. - 1996. - Vol. 67. - P. 461-462.

436. Stephan C, Lein M., Jung К et al. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia // Cancer. - 1997. - Vol. 79. - P. 104-109.

437. Stephenson R.A., Smart C.R., Mineau G.P. et al. The fall in incidence of prostate carcinoma: On the down side of a prostate specific antigen induced peak in incidence — Data from the Utah cancer registry // Cancer. - 1996. - Vol. 77. - P. 1342-1348.

438. Stephenson R.A. The fall in incidence of prostate carcinoma: On the down side of a prostate specific antigen induced peak in incidence —Data from the Utah cancer registry // Cancer. - 1997. - Vol. 79. - P. 189-190.

439. Stewart C.S., Leibovich B.C., Weaver A.L. et al. Prostate cancer diagnosis using a saturation needle biopsy technique after negative sextant biopsies //J. Urol. - 2001. - Vol. 166. - P. 86-91.

440. Stock R.G., Stone N.N., Dewyngaert J.K. et al. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma // Cancer. - 1996. - Vol. 77. - P. 2386-2392.

441. Svetec D., McCabe K., Peretsman S. et al. Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer // J. Urol. - 1998. - Vol. 159. - P. 1606-1608.

442. Takahashi C, Miyagawa L, Kumano S. et al. Detection of telomerase activity in prostate needle biopsy // Eur. Urol. — 1997. — Vol. 32. — P. 494-498.

443. Taneja S.S., Penson D.V., Epelbaum A. et al. Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen? // J. Urol. - 1999. - Vol. 162.-P. 1352-1358.

444. Tchetgen M.B., Song J. Т., Strawderman M. et al. Ejaculation increases the serum prostate-specific antigen concentration // Urology. — 1996.-Vol. 47.-P. 511-516.

445. Terns M.K., Haney D.J., Johnstone I.M. et al. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies // Urology. — 1995. — Vol. 45. - P. 75-80.

446. Terris M.K., Pham Q. Т., Issa MM. et al. Routine transition zone and seminal vesicle biopsies in all patients undergoing TRUS-guided prostate biopsies are not indicated // J. Urol. — 1997. — Vol. 157. — P. 204-206.

447. Terris M.K., Wallen E.M., Stamey T.A. Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer// Urol. Int. - 1997. -Vol. 59. - P. 239-242.

448. Terris M.K. Extended field prostate biopsies: too much of a goodthing? // Urology. - 2000. - Vol. 55. - P. 457-460.

449. Thickman D., Speers W.C., Philpott P.J. et al. Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer//J. Urol. - 1996. -Vol. 156. - P. 110-113.

450. ThielR.P, OesterlingI.E., WojnoKJ. et al. Multicentercomparison of the diagnostic performance of free prostate-specific antigen // Urology. - 1996. - Vol. 48 (Suppl.). - P. 45-50.

451. Thomas G.V., Schrage M.I., Rosen/eld L. et al. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage // J. Urol. - 2000. - Vol. 164. - P. 1987-1991.

452. Поп W.F., Gadban F., Truss M.C. et al. Prostate-specific antigen density-A reliable parameter for the detection of prostate cancer? // Wld. J. Urol. - 1996. - Vol. 14. - P. 53-58.

453. Tochigi T. et al. //Jap. J. Urol. - 2001. - Vol. 92. - P. 609-614.

454. Tollon C, Soulie M., Mouly P. et al. Valeur predictive de la biopsie prostatique // Prog. Urol. - 1995. - Vol. 5 (Suppl. 1). - Abstract. P29.

455. Tombal В., Tajjedine N., OpsomerR. et al. Site specific labeling of sextant biopsy cores helps to predict extracapsular extension of prostate cancer//J. Urol. - 2000. - Vol. 163 (Suppl. 4). - P. 187.

456. Toubert M.E., GuilletJ., Chiron M. et al. Percentage of free serum prostate-specific antigen: A new tool in the early diagnosis of prostatic cancer// Eur. J. Cancer. - 1996. - Vol. 32A. - P. 2088-2093.

457. Trapasso J.G., deKernion J.B., Smith R.B., Dorey F. Incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy//J. Urol. - 1994. - Vol. 152. - P. 1821-1825.

458. Uzzo R.G., Wei J.T., Waldbaum R.S. et al. The influence of prostate size on cancer detection // Urology. - 1995. - Vol. 46. - P. 831-836.

459. Vaidya A., Soloway M.S. Periprostatic local anaesthesia before ultrasound guided prostate biopsy // J. Urol. - 2000. - Vol. 163. - P. 135-138.

460. Vancangh P. J., Denayer P., Devischer L. et al. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ngimi total PSA // Urology. - 1996. - Vol. 48 (Suppl.). - P. 67-70.

461. Vancangh P. J., Denayer P., Sauvage P. et al. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer // Prostate. -1996. - Suppl. 7. - P. 30-34.

462. Vaniersel M. P., Thomas C.M.G., Segers M.F.C. et al. The use of ultrasensitive prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy // Brit. J. Urol. - 1996. - Vol. 77.-P. 418-422.

463. Vaniersel M.P., Witjes W.P.J., Thomas C.M.G. et al. Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen // Prostate. - 1996. - Suppl. 7. - P. 48-57.

464. Vashi A.R., Wojno K.J., Gillespie B. et al. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume // J. Urol. - 1998. - Vol. 159. - P. 920-924.

465. Vaughan E.D., Schlegel P.N., Perlmutter PA. Clinician's manualon prostate-specific antigen (PSA). - London: Science Press, 1999.

466. Veiga E.G., Castelo L.A., Suarez G. et al. Technique of prostatic ultrasound guided biopsies with 10 samples. Is it useful? // Eur. Urol. - 2001. -Vol. 39 (Suppl. 5). - P. 182.

467. VeltriR.W., Miller M.C. Free/total PSA ratios improve differentiation of benign and malignant desease of the prostate: critical analysis of two different test populations // Urology. - 1999. - Vol. 53. - P. 736-745.

468. Walsh P.C. Why make an early diagnosis of prostate cancer? //J. Urol. (Baltimore). - 1992. - Vol. 147. - P. 853.

469. Walsh P.C. Prostate specific antigen after gonadal androgen with drawal and deferred flutamide treatment //J. Urol. (Baltimore). - 1996. - Vol. 155.-P. 1705.

470. Wang M.C, Valenzuela L.A., Murphy G.P. et al. Purification of a human prostate specific antigen // Invest. Urol. - 1979. - Vol. 17. - P. 159-163.

471. Wang T.J., Hill T.M., SokoloffR.L. et al. Dual monoclonal antibody immunoassay for free prostate-specific antigen // Prostate. - 1996. - Vol. 28.-P. 10-16.

472. WangX., Brannigan R.E., RademakerA.W. et al. One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen //J. Urol. - 1997. -Vol. 158. - P. 1431-1435.

473. Watt K., Lee P.-J, M'Timkulu T. et al. Human prostate-specific antigen: Structural and functional similarity with serine proteases // Proc. Nat. Acad. Sci. - 1986. - Vol. 83. - P. 3166-3170.

474. Wills M.L., Hamper U.M., Partin A.W., Epstein JJ. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens // Urology. - 1997. - Vol. 49. - P. 367-373.

475. Wills M.L., SauvageotJ., Partin A.V. et al. Ability of sextant biopsies to predict radical prostatectomy stage // Urology. — 1998. — Vol. 51. — P. 759-764.

476. Wolff J.M., Bares R, Jung P.K. et al. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer // Urol. Int. — 1996.-Vol. 56. -P. 169-173.

477. Wolff J.M., Boeckmann W., Borchers H. et al. Prostate-specific antigen: Insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer // Urol. Int. — 1996. — Vol. 57. — P. 170-174.

478. Wolff J.M., Boeckmann W., Elfert P.J. et al. Clinical use of prostate-specific antigen and prostate-specific antigen density in the staging of patients with cancer of the prostate // Eur. Urol. — 1996. — Vol. 30. — P. 451-457.

479. Wolff J.M., Boeckmann W., Elfert P. et al. Prostate-specific-antigen-density in the evaluation of lymph-node status in clinically localized prostate cancer//Aktuel. Urol.- 1996.-Vol. 27.-P. 136-140.

480. Wolff J.M., Borchers K, Etfert P.J. et al. Free-to-total prostate-specific antigen serum concentrations in patients with prostate cancer and benign prostatic hyperplasia // Brit. J. Urol. - 1996. - Vol. 78. - P. 409-413.

481. Woodrum D., French C, Shamel L.B. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions // Urology. — 1996. — Vol. 48 (Suppl.). — P. 33-39.

482. Wu C.L., Carter N. В., Naqibuddin M. et al. Effect of local anaesthetics on patient recovery after transrectal biopsy // Urology. — 2001. — Vol. 57. - P. 925-929.

483. Yorukoglu K., SagolO., Ozkara E. et al. Comparison of microvascularization in diagnostic needle biopsies and radical prostatectomies in prostate carcinoma // Eur. Urol. - 1999. - Vol. 35. - P. 109-112.

484. Zincke H. Impact of prostate-specific antigen screening on prostate cancer // Urology. - 1996. - Vol. 47. - P. 783.

485. Zlotta A., Djavan В., Ekane S. et al. Is one set of sextant biopsies enough to rale out prostate cancer? A prospective study on the influence of transition and total prostate volumes on prostate cancer yield // Eur. Urol. - 2000. - Vol. 37 (Suppl. 2). - Abstr. 295.

---